Clinical Report: Evaluating the Safety Profile of Etomidate
Background
Etomidate is a commonly used intravenous anesthetic known for its rapid onset and minimal cardiovascular effects, making it suitable for high-risk patients. However, concerns regarding its safety profile, particularly beyond adrenal suppression, necessitate ongoing surveillance.
Data Highlights
Adverse Event
Count
Cardiac Arrest
33
Seizure
12
Drug Abuse
10
Hypokalaemia
9
Bruxism
9
Cardiac Disorders
100
Endocrine Disorders
38
Key Findings
318 ADRs were identified from the FAERS database.
59 preferred terms and 2 system organ classes met the criteria of all four disproportionality algorithms.
Cardiac disorders were significantly associated with etomidate, with 100 reports noted.
Endocrine disorders were identified as a novel signal with 38 reports.
Clinical Implications
Healthcare professionals should maintain heightened vigilance regarding the potential for serious ADRs associated with etomidate, particularly in high-risk populations. Continuous monitoring and reporting of adverse events are essential for ensuring patient safety.
Conclusion
This study confirmed known risks and identified novel ADRs of etomidate.
